External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.05/sh (unrisked $7.50/sh).</li><li>Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC) programs over the past month.</li><li>This has provided a basis for further de-risking of their therapeutic development pipeline and re-analysis of the PSMA PET Dx market from an indication basis (focused on BCR) where Clarity’s agent may take a disproportionate share of the market if they can prove clinical superiority. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.05/sh (unrisked $7.50/sh).Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC) programs over the past month.This has provided a basis for further de-risking of their therapeutic development pipeline and re-analysis of the PSMA PET Dx market from an indication basis (focused on BCR) where Clarity’s agent may take a disproportionate share of the market if they can prove clinical superiority. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - More SECuRE than Ever